Integral Health Asset Management LLC Acquires 400,000 Shares of REGENXBIO Inc. $RGNX

Integral Health Asset Management LLC lifted its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 57.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,100,000 shares of the biotechnology company’s stock after purchasing an additional 400,000 shares during the quarter. Integral Health Asset Management LLC owned 2.17% of REGENXBIO worth $10,615,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its stake in shares of REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after buying an additional 1,270 shares during the last quarter. Profund Advisors LLC boosted its holdings in shares of REGENXBIO by 11.8% in the 3rd quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 1,523 shares during the last quarter. Pale Fire Capital SE grew its stake in shares of REGENXBIO by 7.7% in the second quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 2,000 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of REGENXBIO in the third quarter valued at $25,000. Finally, BNP Paribas Financial Markets grew its position in shares of REGENXBIO by 18.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,724 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 2,800 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on RGNX shares. Morgan Stanley dropped their target price on shares of REGENXBIO from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. The Goldman Sachs Group decreased their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. HC Wainwright cut their target price on shares of REGENXBIO from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Barclays began coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price target on the stock. Finally, Leerink Partners increased their price target on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and a consensus target price of $27.50.

Key Headlines Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Phase 1/2 AFFINITY interim data for RGX‑202 showed early efficacy signals and the company reported no evidence of liver injury in the study — a material safety datapoint that supports the program’s clinical outlook. Positive interim data for Regenxbio’s gene therapy in DMD
• Neutral Sentiment: Insider activity: director/officer Steve Pakola sold 5,124 shares at about $10.35 (disclosed 3/12–3/13). The sale is small (~2% reduction of his holding) but attracts attention in a thinly traded, volatile name. REGENXBIO Insider Sells
• Negative Sentiment: Multiple law firms have filed or are soliciting class‑action claims against REGENXBIO covering a multi‑year period (lead‑plaintiff deadlines around April 14, 2026). The wave of filings raises settlement/legal risk and creates sustained headline pressure. Schall Law Firm class action notice
• Negative Sentiment: Analyst/headline pressure: HC Wainwright published a bearish Q1 earnings forecast, adding sell‑side pressure after REGENXBIO’s recent March 5 quarter where EPS and revenue missed consensus — a reminder of near‑term execution and cash‑flow risks that can weigh on valuation. HC Wainwright bearish forecast

Insider Buying and Selling

In other REGENXBIO news, insider Steve Pakola sold 5,124 shares of REGENXBIO stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $10.35, for a total value of $53,033.40. Following the completion of the transaction, the insider directly owned 247,926 shares of the company’s stock, valued at $2,566,034.10. The trade was a 2.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.79% of the stock is currently owned by company insiders.

REGENXBIO Stock Down 5.6%

Shares of NASDAQ:RGNX opened at $8.57 on Friday. REGENXBIO Inc. has a 12-month low of $5.03 and a 12-month high of $16.19. The company’s 50 day moving average price is $11.00 and its two-hundred day moving average price is $11.43. The firm has a market cap of $442.30 million, a PE ratio of -2.28 and a beta of 1.08.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). The business had revenue of $30.34 million during the quarter, compared to analyst estimates of $45.48 million. REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. On average, research analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.